235 related articles for article (PubMed ID: 33734003)
1. MPPED2 is downregulated in glioblastoma, and its restoration inhibits proliferation and increases the sensitivity to temozolomide of glioblastoma cells.
Pellecchia S; De Martino M; Esposito F; Quintavalle C; Fusco A; Pallante P
Cell Cycle; 2021 Apr; 20(7):716-729. PubMed ID: 33734003
[TBL] [Abstract][Full Text] [Related]
2. miR-140 targeting CTSB signaling suppresses the mesenchymal transition and enhances temozolomide cytotoxicity in glioblastoma multiforme.
Ho KH; Cheng CH; Chou CM; Chen PH; Liu AJ; Lin CW; Shih CM; Chen KC
Pharmacol Res; 2019 Sep; 147():104390. PubMed ID: 31398406
[TBL] [Abstract][Full Text] [Related]
3. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
4. miR-126-3p sensitizes glioblastoma cells to temozolomide by inactivating Wnt/β-catenin signaling via targeting SOX2.
Luo W; Yan D; Song Z; Zhu X; Liu X; Li X; Zhao S
Life Sci; 2019 Jun; 226():98-106. PubMed ID: 30980849
[TBL] [Abstract][Full Text] [Related]
5. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
6. Loss of programmed cell death 10 activates tumor cells and leads to temozolomide-resistance in glioblastoma.
Nickel AC; Wan XY; Saban DV; Weng YL; Zhang S; Keyvani K; Sure U; Zhu Y
J Neurooncol; 2019 Jan; 141(1):31-41. PubMed ID: 30392087
[TBL] [Abstract][Full Text] [Related]
7. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
Zhang D; Dai D; Zhou M; Li Z; Wang C; Lu Y; Li Y; Wang J
Cell Physiol Biochem; 2018; 51(6):2496-2508. PubMed ID: 30562739
[TBL] [Abstract][Full Text] [Related]
9. The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells.
Mazor G; Levin L; Picard D; Ahmadov U; Carén H; Borkhardt A; Reifenberger G; Leprivier G; Remke M; Rotblat B
Cell Death Dis; 2019 Mar; 10(3):246. PubMed ID: 30867410
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
11. Exosomal transfer of miR-151a enhances chemosensitivity to temozolomide in drug-resistant glioblastoma.
Zeng A; Wei Z; Yan W; Yin J; Huang X; Zhou X; Li R; Shen F; Wu W; Wang X; You Y
Cancer Lett; 2018 Nov; 436():10-21. PubMed ID: 30102952
[TBL] [Abstract][Full Text] [Related]
12. PPAR-γ agonists reactivate the ALDOC-NR2F1 axis to enhance sensitivity to temozolomide and suppress glioblastoma progression.
Chang YC; Chan MH; Li CH; Chen CL; Tsai WC; Hsiao M
Cell Commun Signal; 2024 May; 22(1):266. PubMed ID: 38741139
[TBL] [Abstract][Full Text] [Related]
13. Exploring the Functional Roles of Telomere Maintenance 2 in the Tumorigenesis of Glioblastoma Multiforme and Drug Responsiveness to Temozolomide.
Feng SW; Wu ZS; Chiu YL; Huang SM
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298208
[TBL] [Abstract][Full Text] [Related]
14. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells.
Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N
J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502
[TBL] [Abstract][Full Text] [Related]
15. The DNA repair protein ALKBH2 mediates temozolomide resistance in human glioblastoma cells.
Johannessen TC; Prestegarden L; Grudic A; Hegi ME; Tysnes BB; Bjerkvig R
Neuro Oncol; 2013 Mar; 15(3):269-78. PubMed ID: 23258843
[TBL] [Abstract][Full Text] [Related]
16. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
Wu Q; Cao Z; Xiao W; Zhu L; Xie Q; Li L; Zhang B; Zhao W
Cell Physiol Biochem; 2018; 51(6):2536-2546. PubMed ID: 30562758
[TBL] [Abstract][Full Text] [Related]
17. MPC1 deletion is associated with poor prognosis and temozolomide resistance in glioblastoma.
Chai Y; Wang C; Liu W; Fan Y; Zhang Y
J Neurooncol; 2019 Sep; 144(2):293-301. PubMed ID: 31236818
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.
Zhou M; Sareddy GR; Li M; Liu J; Luo Y; Venkata PP; Viswanadhapalli S; Tekmal RR; Brenner A; Vadlamudi RK
Sci Rep; 2019 Apr; 9(1):6124. PubMed ID: 30992459
[TBL] [Abstract][Full Text] [Related]
19. Micro-RNA29b enhances the sensitivity of glioblastoma multiforme cells to temozolomide by promoting autophagy.
Xu JX; Yang Y; Zhang X; Luan XP
Anat Rec (Hoboken); 2021 Feb; 304(2):342-352. PubMed ID: 32275350
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]